Loading…
PROCEPT BioRobotics Corporation is projected to rise to $23.11 by 2027, a +15% move from its current price of $20.12. PRCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $19.38 | $20.13 | $20.90 | +0.06% |
| Jul 14 | $19.09 | $20.14 | $21.24 | +0.13% |
| Jul 15 | $18.88 | $20.15 | $21.51 | +0.19% |
| Jul 16 | $18.70 | $20.17 | $21.75 | +0.25% |
| Jul 17 | $18.55 | $20.18 | $21.96 | +0.32% |
| Jul 18 | $18.41 | $20.19 | $22.15 | +0.38% |
| Jul 19 | $18.28 | $20.20 | $22.33 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.28 | $20.20 | $22.33 | +0.45% |
| Week 2 | $17.62 | $20.29 | $23.37 | +0.89% |
| Week 3 | $17.15 | $20.38 | $24.23 | +1.34% |
| Week 4 | $16.77 | $20.48 | $25.00 | +1.79% |
| Week 5 | $16.45 | $20.57 | $25.71 | +2.25% |
| Week 6 | $16.18 | $20.66 | $26.38 | +2.70% |
| Week 7 | $15.93 | $20.75 | $27.03 | +3.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PROCEPT BioRobotics Corporation is a healthcare company that develops surgical robotics solutions for urology in the United States and internationally. It designs, manufactures, and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The HYDROS Robotic System provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.
PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. The company operates in the Healthcare sector, bringing robotic technologies to urologic procedures across markets.
PROCEPT BioRobotics Corporation (PRCT) is currently priced at $19.80 with a market capitalization of $1.13B and a rank of 2476. The stock sits in a smaller market-cap tier and carries a defined price point relative to peers in healthcare robotics.
The near-term picture shows a neutral stance for 2026, with a 30-day price range of $15.40 to $25.44. The current price aligns with the 30-day support at $19.80 and faces resistance near $29.09, framing a cautious short-term outlook.
Longer-term, the forecast depicts a bullish trajectory starting in the early 2030s and extending through 2050, with progressively higher average prices and sizable ROI potential. Notably, the path includes several years of meaningful upside, culminating in substantial gains by 2050.
A major floor 30.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 44.6% above — a clean break opens room to run.
A major ceiling 62.0% above — clearing it would confirm fresh momentum.
Key PRCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.53 | Sell | $20.67 | Sell |
| MA 10 | $21.49 | Sell | $21.18 | Sell |
| MA 20 | $22.01 | Sell | $22.23 | Sell |
| MA 50 | $24.74 | Sell | $23.94 | Sell |
| MA 100 | $25.08 | Sell | $25.76 | Sell |
| MA 200 | $28.82 | Sell | $30.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.89 | Neutral |
| Stoch RSI (14) | 57.20 | Neutral |
| CCI (20) | -54.17 | Neutral |
| Williams %R (14) | -69.35 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | 1.41 | Buy |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 30.65 | Neutral |
| TRIX (15) | -0.76 | Sell |
| Awesome (5,34) | -3.81 | Sell |
| Ultimate (7,14,28) | 39.19 | Neutral |
| Momentum (10) | -0.60 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 19.64 | Buy |
| ADX (14) | 20.51 | Sell |
| ATR (14) | 0.81 | Info |
The 30-day technical picture is Bearish with an RSI14 of 30, indicating cautious momentum. The moving averages sit at SMA50 $24.87 and SMA200 $28.99, underscoring a tilt toward consolidation rather than upside breakout in the immediate term.
Support is identified at $19.80 and resistance at $29.09, framing the key near-term barriers. The 30-day range runs from $15.40 to $25.44, highlighting elevated volatility and a broad price channel for PRCT. Annualized volatility is 70, signaling higher-than-average price swings over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.75 | $20.12 | $27.68 | 0% | Neutral | |
| $17.74 | $23.11 | $32.20 | +15% | Neutral | |
| $16.22 | $22.00 | $32.17 | +9% | Neutral | |
| $16.33 | $22.90 | $34.78 | +14% | Neutral | |
| $15.46 | $22.35 | $35.02 | +11% | Neutral | |
| $16.09 | $23.90 | $38.49 | +19% | Neutral | |
| $19.77 | $30.15 | $49.73 | +50% | Bullish | |
| $20.79 | $32.49 | $54.77 | +62% | Bullish | |
| $20.47 | $32.75 | $56.32 | +63% | Bullish | |
| $18.41 | $30.14 | $52.80 | +50% | Bullish | |
| $25.29 | $46.01 | $87.04 | +129% | Bullish | |
| $39.04 | $86.06 | $181.74 | +328% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $19.75 | $20.12 | $24.59 | +0.00% |
| August 2026 | $17.10 | $20.40 | $25.14 | +1.40% |
| September 2026 | $17.69 | $21.31 | $26.66 | +4.50% |
| October 2026 | $18.37 | $22.32 | $28.27 | +4.71% |
| November 2026 | $17.92 | $21.92 | $28.07 | -1.77% |
| December 2026 | $17.39 | $21.42 | $27.68 | -2.31% |
Click any year to see its month-by-month PRCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PRCT could reach as high as $27.68, with a base case around $20.12 and support toward $19.75 — roughly 0% from $20.12. Price action looks broadly range-bound.
Expect PRCT to range from $17.74 to $32.20 through 2027. The $23.11 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The PRCT price prediction for 2028 points to an average of $22.00 (low $16.22, high $32.17) — a potential gain of +9% on today's $20.12. Price action looks broadly range-bound.
In 2029, PRCT is projected to trade between $16.33 and $34.78, averaging $22.90 — a potential gain of +14% from today's $20.12. That is up +4% on the projected 2028 average. A consolidation phase looks the most probable path here.
PROCEPT BioRobotics Corporation's 2030 outlook centres on $22.35, within a $15.46 to $35.02 range. That is -2% versus the projected 2029 average. That marks a +11% change versus current levels. Price action looks broadly range-bound.
By 2031, PRCT could reach as high as $38.49, with a base case around $23.90 and support toward $16.09 — roughly +19% from $20.12. A consolidation phase looks the most probable path here.
Expect PRCT to range from $19.77 to $49.73 through 2032. The $30.15 average target implies a +50% move from current prices. That is up +26% on the projected 2031 average. Momentum favours further upside here.
The PRCT price prediction for 2033 points to an average of $32.49 (low $20.79, high $54.77) — a potential gain of +62% on today's $20.12. Buyers look set to stay in control over this stretch.
In 2034, PRCT is projected to trade between $20.47 and $56.32, averaging $32.75 — a potential gain of +63% from today's $20.12. That is up +1% on the projected 2033 average. Momentum favours further upside here.
PROCEPT BioRobotics Corporation's 2035 outlook centres on $30.14, within a $18.41 to $52.80 range. That is -8% versus the projected 2034 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PRCT could reach as high as $87.04, with a base case around $46.01 and support toward $25.29 — roughly +129% from $20.12. Momentum favours further upside here.
Expect PRCT to range from $39.04 to $181.74 through 2050. The $86.06 average target implies a +328% move from current prices. That is up +87% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRCT today (≈ 49.714144 PRCT) could be worth
$4,278.59
+$3,278.59 (+328%) by 2050 · US Dollar
Based on the average projected PRCT price of $86.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRCTwould be worth at today's price.
$1,000 invested in PRCT on Jul 10, 2025 (≈ 16.889039 PRCT) would be worth
$339.72
-$660.28 (-66.0%) today · 0.34× · US Dollar
Based on a PRCT entry price of $59.21 vs. today's $20.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.03 | $956.49 | -4.4% |
| 1 month ago | $29.09 | $691.47 | -30.9% |
| 3 months ago | $23.2 | $867.03 | -13.3% |
| 6 months ago | $31.33 | $642.04 | -35.8% |
| 1 year ago | $59.21 | $339.72 | -66.0% |
| All time (4.8y) ago | $41.94 | $479.61 | -52.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRCT forecast.
Our base-case forecast reaches $40.00 around 2040.
Implied market cap at $40.00: $2.28B
The year-by-year forecast shows a gradual rise from 2026 onward, with the 2026 min, avg, and max all anchored around $19.80 to $27.30 and a 0 ROI, reflecting a neutral tone. In 2027 the price path broadens, with an average of $22.80 and a max of $31.83, delivering a 15.2 ROI. The 2028 and 2029 forecasts continue to grow modestly, with 2028 averaging $21.60 and max $31.66 (ROI 9.1), and 2029 averaging $22.58 with a max of $34.37 (ROI 14.1).
The 2030 forecast shows an average of $22.05 with a max of $34.64 (ROI 11.4), followed by 2031 with an average of $23.51 and a max of $37.95 (ROI 18.8). Beginning in 2032, the outlook turns bullish, with a 2032 average of $29.89 and max $49.44 (ROI 51); 2033 averages $32.17 with a max of $54.39 (ROI 62.5); 2034 averages $32.22 and max $55.58 (ROI 62.8); and 2035 averages $29.80 with a max of $52.37 (ROI 50.5).
The bullish trend strengthens further into the next decade, with 2040 averaging $45.46 and max $86.30 (ROI 129.7), and 2050 averaging $85.47 with a max of $181.18 (ROI 331.8). These figures illustrate a substantial upside potential over the longer term, tempered by the inherent uncertainty in any forecast.
Tap a question to reveal the answer.
2026 min $19.80, avg $19.80, max $27.30, ROI 0, sentiment NEUTRAL.
Near term is NEUTRAL for 2026 with gradual upside potential beginning in 2027 (avg $22.80, max $31.83; ROI 15.2). From 2032 onward, the forecast turns BULLISH with higher averages (e.g., 2032 avg $29.89; 51 ROI) and continuing gains through 2050 (2033 avg $32.17; 2034 avg $32.22; 2040 avg $45.46; 2050 avg $85.47; ROI 331.8). These are estimates, not guarantees.
Yes. The forecast shows 2033 max at $54.39 and 2034 max at $55.58, indicating periods where the price could exceed $50.
Current price is $19.80 and market cap is $1.13B.
The 30-day range is $15.40 to $25.44 and the annualized volatility is 70.
PROCEPT BioRobotics Corporation Community Discussion
0Share your PROCEPT BioRobotics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.